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Indications for gadolinium for
coronary angiography
To the Editor:
We read with great interest the article by
Nicolosi and associates1 in the July 2002
issue of the Journal dealing with the ben-
eficial effects of gadolinium on regional
stunning in the canine heart in vivo.
Gadolinium is currently used to en-
hance magnetic resonance imaging and is
known to be well tolerated by the kidneys.
We2 recently reported the first clinical use
of gadolinium for coronary angiography in
a patient with elevated serum creatinine.
We are currently conducting a prospective
randomized trial to evaluate the exact role
as well as the safety of gadolinium for
coronary angiography in patients with ab-
normal renal function. Although none of
our patients had any enzymatic or electro-
cardiographic changes in relation to myo-
cardial damage, we are still wondering
what the exact effects of this drug are on
the myocardium. The article by Nicolosi
and colleagues suggests that gadolinium is
beneficial for the myocardium. This article,
together with the promising results of our
ongoing trial, might pave the way toward
future indications for gadolinium for coro-
nary angiography.
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Reply to the Editor
In response to the letter to the Editor re-
garding our article,1 we find the notion of
using a gadolinium-based contrast agent
for coronary angiography intriguing, par-
ticularly in the context of acute coronary
syndrome. Our study documented the sal-
utary effect of gadolinium chloride (GdCl3),
administered before an ischemic insult, on
contractile function after 3 hours of reper-
fusion. There was no observed effect of
gadolinium on a load-independent index of
contractility in the baseline state, nor were
there effects on heart rate or cardiac output.
The mechanism(s) by which gadolinium
accelerates recovery of contractile function
in stunned myocardium are yet to be deter-
mined. Its may modulate ischemia/reperfu-
sion–induced pathophysiology of intracel-
lular ions, particularly Ca2, via effects on
stretch-activated ion channels, and/or it
may directly attenuate superoxide produc-
tion. These effects, however, have been
observed only with the use of GdCl3. The
gadolinium chelates used as contrast agents
for magnetic resonance imaging and used
by Sarkis and associates3 for coronary an-
giography are generally eliminated by the
kidney unmetabolized. These agents do not
bind plasma proteins, nor are they thought
to react with biologic structures. One can-
not assume that these chelates would exert
effects similar to those of GdCl3. Further
studies of gadolinium chelates would there-
fore be necessary before considering them
for possible dual roles as both contrast
agents and protective agents in coronary
artery disease.
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Risk adjustment in analysis of
surgery for congenital heart disease
To the Editor:
The article by Jenkins and associates,1 in
the July 2002 issue of the Journal, is
clearly an important advancement in risk
adjustment when analyzing mortality out-
come in the field of surgery for congenital
heart disease. Further statistical analysis is
needed in centers with high case volumes
as the RACHS (Risk Adjustment in Con-
genital Heart Surgery) methodology
evolves.
The concern regarding the large spec-
trum of mortality among risk categories 2
to 4, with some institutions displaying a
threshold increase or decrease in mortality
as higher-risk procedures, is disturbing for
a potential severity model. This mismatch
of observed/expected ratios is not surpris-
ing for severity scores in surgery in gener-
al.2 Several factors involved that stem from
inherent surgical practice and original lo-
gistic regression model of 5 variables were
not discussed in the article.
The inherent surgical practice could be
divided into physiologic and operative fea-
tures. The operative variables, including
in-hospital redo cases and estimated blood
loss, should be evaluated. The first can
have a dual knock effect on mortality. The
estimated blood loss factor can have direct
effects by contributing to child hypoxia and
later the side effects of blood transfusion.
Multivariate preoperative physiologic vari-
ables were not described in the original
article by Jenkins and coworkers,3 for ex-
ample, hemoglobin, plasma sodium, and
potassium. Recently, a hemoglobin con-
centration of 100 g/L or less had a 5-fold
higher in-hospital mortality rate that those
with higher concentrations.4
A widely recognized European severity
score, POSSUM (a Physiological and Op-
erative Severity Score for the enUmeration
of Mortality and morbidity), used in vascu-
lar and colorectal surgery, is a simple scor-
ing system incorporating only a total of 18
variables, of which preoperative electro-
lytes determined outcome.5 There may be
room for more specific and relevant vari-
ables to be included in RACHS-1.
Another aspect that could lead to the
diversity of outcome in the intermediate
risk category factors is whether a linear
versus exponential model was adopted in
the original equation. A linear method of
analysis of the risk for each mortality group
is artificially taken to the median as op-
posed to the mean in that risk category
group. Although it may apply well to high-
risk patients with smaller n values, it may
overpredict death in the low-risk popula-
tion, as was illustrated in centers A, F, O, S,
and U in category 2 versus 3 and 4. Rean-
alyzing the data may produce different
trends.
It is possible that these factors were
considered; however, a discussion of these
factors would be necessary for the reader.
This would reduce chance-related outcome
and might revisit the question regarding
institutional inquiries, especially with re-
gard to assignment of certain types of cases
to specific surgeons and location of post-
operative care.
Jeffrey H. Shuhaiber, MD
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Ranking institutions
To the Editor:
Jenkins and Gauvreau1 illustrated the use
of a novel risk adjustment method in con-
genital heart surgery and chose to present
their results largely in terms of institutional
rankings. However, ranks are a notoriously
inaccurate comparator for performance—
someone always has to be bottom and top
of a league table, no matter how much the
play of chance may have contributed to
their performance. Figure 1 shows the risk-
adjusted standardized mortality ratios
(SMRs) with 95% confidence intervals, as
ranked by Jenkins and Gauvreau1 accord-
ing to outcomes from 22 institutions in
1996. We first note that a formal test that
all the centers have SMRs of precisely 1 is
barely significant (2  35.6, df  22, P 
.03, after transformation of all values to
power 0.3 to bring to approximate normal-
ity), so there is not even strong evidence of
any heterogeneity among centers. We can
also estimate the “true rank” of each center.
This requires the methodology described
by Marshall and Spiegelhalter,2 in which
the “true SMRs” are repeatedly simulated
from the confidence intervals in Figure 1
and then ranked at each iteration of the
simulation. The resulting estimated true
ranks and their 95% confidence intervals
TABLE 1. Probabilities of being “true best” and “true worst” centers for the 8
highest and lowest ranking centers
Center
Probability that “true
best” center Center
Probability that “true
worst” center
C 0.27 J 0.01
D 0.16 Q 0.01
H 0.20 L 0.06
E 0.06 A 0.15
M 0.03 O 0.09
F 0.11 N 0.05
G 0.00 P 0.27
S 0.12 B 0.21
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